MTA
Metalla Royalty & Streaming Ltd.$7.66
LiveJun 15, 2026
Market cap
$715.77M
52w range
3.44 – 9.25
P / E
—
EPS
—
Volume
471.11K
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Metalla Royalty & Streaming Ltd.’s valuation06-15today
- IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers22h
- IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers22h
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $7.50 (-2.09%)
Candlestick · 1Y
Open in chart workstation →MTA
7.31-3.56%H 9.25L 5.95MA50 7.30MA200 —Avg vol 544K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.79% | +15.19% | +12.48% | -0.13% | -3.04% | -1.54% | +114.57% | +81.09% | -24.90% | +1579.82% | +596.36% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$7.51
Bid
$7.27
200 sh
Ask
$8.06
100 sh
Spread
$0.790
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Financial Services+1.26%
- Utilities+0.83%
- Communication Services+0.46%
- Energy+0.45%
- Technology+0.34%
- Consumer Defensive-0.21%
- Industrials-0.32%
- Healthcare-0.39%
- Real Estate-0.67%
- Consumer Cyclical-0.94%
- Basic Materials-1.06%
Top industries (issuer's industry highlighted)
No industry data returned.
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancersprnewswire.com·Jun 15, 2026
- IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancersprnewswire.com·Jun 15, 2026
Peers
No peer list available for MTA.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|